ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Also written as “Infanrix hexa”, “DTPa-HBV-IPV/Hib” and “Infanrix™ hexa”.

Its studies are mostly in Hepatitis B · Diphtheria · Streptococcal Infections · Poliomyelitis · Meningococcal Infections, led by 4 companies.

Drug pageDiphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine: every studyAll 29 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 29, 200827 company-led studies, 2 open or runningNext primary completion: May 17, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only230 open or runningphase 4since Jan 29, 2008Sep 13, 2005none ahead
Pfizerits history only21 open or runningphase 4since Feb 17, 2006Feb 17, 2006Nov 6, 2028phase 3 · NCT07160244
Merckits history only10 open or runningphase 3since Feb 5, 2007Feb 5, 2007none ahead
Sanofiits history only11 open or runningphase 2since Oct 16, 2024Oct 16, 2024May 17, 2027phase 2 · NCT06647407

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Sep 13, 2005.

  1. Jan 29, 2008Phase 4 study in PoliomyelitisGlaxoSmithKline · NCT00611559 · 283 enrolled · Russian Federation
  2. Feb 15, 2008Phase 3 study in Streptococcal InfectionsGlaxoSmithKline · NCT00624819 · 524 enrolled · Poland
  3. Feb 20, 2008Phase 2 study in DiphtheriaGlaxoSmithKline · NCT00627458 · 403 enrolled · Finland
  4. Sep 12, 2008Phase 4 study in Hepatitis BGlaxoSmithKline · NCT00753649 · 224 enrolled · Canada
  5. May 12, 2011Phase 3 study in PoliomyelitisGlaxoSmithKline · NCT01353703 · 224 enrolled · India
  6. Oct 13, 2011Phase 4 study in Hepatitis BGlaxoSmithKline · NCT01457547 · 494 enrolled · Finland, Italy, Sweden
  7. Oct 13, 2011Phase 2 study in Hepatitis BGlaxoSmithKline · NCT01457495 · 312 enrolled
  8. Oct 20, 20112 phase 3 studies in Hepatitis BGlaxoSmithKline · NCT01457560, NCT01457508
  9. Mar 21, 2014Phase 3 study in PoliomyelitisGlaxoSmithKline · NCT02096263 · 585 enrolled · United States
  10. Mar 19, 2015Phase 4 study in TetanusGlaxoSmithKline · NCT02422264 · 601 enrolled · Australia, Canada, Czechia and more
  11. Jul 14, 2016Phase 4 study in DiphtheriaGlaxoSmithKline · NCT02853929 · 551 enrolled · Australia, Canada, Czechia and more
  12. Aug 27, 2020Phase 4 study in DiphtheriaGlaxoSmithKline · NCT04535037 · 500 enrolled · Germany, Italy, Spain
  13. Oct 16, 2024Sanofi’s first study: phase 2 study in Meningococcal ImmunizationNew to SanofiSanofi · NCT06647407 · 750 enrolled · Brazil, Czechia, Denmark and more
  14. Aug 14, 2025Phase 3 study in HealthyPfizer · NCT07160244 · 6,000 planned · United States, Argentina, Brazil and more

Ahead

  1. May 17, 2027Primary completion: phase 2 study in Meningococcal ImmunizationSanofi · NCT06647407
  2. Nov 6, 2028Primary completion: phase 3 study in HealthyPfizer · NCT07160244

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07160244Healthy · United States, Argentina, Brazil and more3RecruitingPfizerNov 6, 20286,000
NCT06647407Meningococcal Immunization · Brazil, Czechia, Denmark and more2Active, not recruitingSanofiMay 17, 2027750
NCT04535037Diphtheria · Germany, Italy, Spain4CompletedGlaxoSmithKlineJul 25, 2022500
NCT02853929Diphtheria · Australia, Canada, Czechia and more4CompletedGlaxoSmithKlineMar 19, 2019551
NCT02422264Tetanus · Australia, Canada, Czechia and more4CompletedGlaxoSmithKlineMar 7, 2018601
NCT02096263Poliomyelitis · United States3CompletedGlaxoSmithKlineFeb 6, 2015585
NCT01457560Hepatitis B3CompletedGlaxoSmithKlineApr 200180
NCT01457508Hepatitis B3CompletedGlaxoSmithKlineMar 2000440
NCT01457547Hepatitis B · Finland, Italy, Sweden4CompletedGlaxoSmithKlineMay 2005494
NCT01457495Hepatitis B2CompletedGlaxoSmithKlineSep 1999312
NCT01353703Poliomyelitis · India3CompletedGlaxoSmithKlineFeb 25, 2013224
NCT00753649Hepatitis B · Canada4CompletedGlaxoSmithKlineMar 12, 2013224
NCT00627458Diphtheria · Finland2CompletedGlaxoSmithKlineAug 18, 2008403
NCT00624819Streptococcal Infections · Poland3CompletedGlaxoSmithKlineJun 2, 2008524
NCT00611559Poliomyelitis · Russian Federation4CompletedGlaxoSmithKlineJun 25, 2008283
NCT00533507Rotavirus Infections · Taiwan3CompletedGlaxoSmithKlineJun 1, 2008230
NCT00508261Meningococcal Infections · Austria, Germany, Greece3CompletedGlaxoSmithKlineMay 26, 2008793
NCT00489554Streptococcal Infections · Mexico3CompletedGlaxoSmithKlineMar 31, 2008230
NCT00463437Hepatitis B · Germany, Poland, Spain3CompletedGlaxoSmithKlineJan 21, 20081,437
NCT00432042Chickenpox · Germany, Italy3CompletedMerckMar 27, 2008955
NCT00390910Streptococcal Infections · Greece, Spain3CompletedGlaxoSmithKlineJul 2, 2007286
NCT00366366Hepatitis B3CompletedGlaxoSmithKlineSep 2002150
NCT00370318Rotavirus Infections · Czech Republic3CompletedGlaxoSmithKline400
NCT00294294Fever4CompletedPfizerDec 2006300
NCT00289796Hepatitis B · Germany2CompletedGlaxoSmithKlineApr 2006121
NCT00325143Haemophilus Infections · Singapore3CompletedGlaxoSmithKlineFeb 1, 2007702
NCT00196976Meningococcal Infections · Austria, Greece2CompletedGlaxoSmithKlineMar 1, 2006461

How it is read

Names in the registry

  • “Infanrix hexa”, 10 entries
  • “DTPa-HBV-IPV/Hib”, 3 entries
  • “Infanrix™ hexa”, 3 entries
  • “Infanrix Hexa”, 2 entries
  • “DTPa-HBV-IPV/Hib (Infanrix hexa™)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.